Reports Q3 revenue $153.88M, consensus $146.14M. “Our third-quarter performance underscores the strength of our growth products, with combined Qelbree and GOCOVRI net product sales increasing 52% in the third quarter of 2023 compared to the same period last year,” said Jack Khattar, president and CEO of Supernus. “In addition to our strong commercial execution, during our R&D Day in October 2023, we highlighted our pipeline of first-in-class differentiated CNS product candidates that have the potential to bolster future growth.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SUPN:
- Supernus Announces Third Quarter 2023 Financial Results
- Supernus to Participate in the Jefferies London Healthcare Conference
- Supernus Pharmaceuticals (SUPN) Q3 Earnings Cheat Sheet
- Supernus announces SPN-830 NDA accepted for review by FDA
- Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA